Feed GXI.DE
GX

Gerresheimer GXI.DE XETRA · Healthcare · Germany

31.96 € +2.37% +0.74 €

Summary

37 / 100 · Bulios Score

What speaks for it

  • Out of every 100 EUR of revenue, 16 EUR is left as free cash.
  • The price moves less than the market (beta 0.47).

What to watch

  • The company made a loss over the last 12 months.
  • Repaying its net debt would take 8.6 years of operating profit.
  • The share price is above the Bulios Fair Price.
  • It missed profit estimates 5 times in the last 8 quarters.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive
Bulios Fair Price
Current price 31.96 €

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

The company made a loss over the last 12 months, so there is no profit to set the price against.

Valuation in detail

Is it growing?

Slowly

Revenue (EUR)

Diluted EPS (EUR)

  • Analyst estimate

Revenue grew by 10% a year over 5 years. Over the last 3 years it grew by 8.5% a year. For the next fiscal year analysts expect revenue to grow by 0.9%.

Growth in detail

Does it make money?

Poorly

Over the last 12 months it made a loss of 400.6M €.

Profitability in detail

Is it financially healthy?

Mostly

Repaying all its debt would take 6.0 years of free cash flow. Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

No coverage

No analyst covers this stock.

Analysts in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy